Azzad Asset Management Inc. ADV Takes $831,000 Position in Charles River Laboratories International, Inc. $CRL

Azzad Asset Management Inc. ADV purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 5,311 shares of the medical research company’s stock, valued at approximately $831,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its holdings in Charles River Laboratories International by 82.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 650 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 294 shares in the last quarter. Canada Post Corp Registered Pension Plan lifted its stake in shares of Charles River Laboratories International by 1,363.2% in the third quarter. Canada Post Corp Registered Pension Plan now owns 9,072 shares of the medical research company’s stock worth $1,333,000 after buying an additional 8,452 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of Charles River Laboratories International by 10.0% in the third quarter. Bessemer Group Inc. now owns 5,036 shares of the medical research company’s stock worth $788,000 after buying an additional 458 shares in the last quarter. Hantz Financial Services Inc. boosted its position in Charles River Laboratories International by 11.2% during the third quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company’s stock worth $124,000 after acquiring an additional 80 shares during the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in Charles River Laboratories International during the 3rd quarter valued at about $533,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on CRL. Argus set a $200.00 target price on shares of Charles River Laboratories International in a research note on Monday, November 17th. Barclays increased their price target on Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Evercore boosted their price objective on Charles River Laboratories International from $250.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Finally, TD Cowen reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Thursday, January 22nd. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $209.46.

Charles River Laboratories International Price Performance

CRL stock opened at $185.53 on Tuesday. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $228.88. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The stock has a market cap of $9.13 billion, a price-to-earnings ratio of -118.93, a price-to-earnings-growth ratio of 5.67 and a beta of 1.63. The business has a fifty day moving average of $204.51 and a two-hundred day moving average of $180.02.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.